New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 4, 2014
10:23 EDTPETM, BLDP, ODP, FCEL, TRGTHigh option volume stocks: FCEL BLDP TRGT ODP PETM
News For FCEL;BLDP;TRGT;ODP;PETM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 17, 2015
09:37 EDTFCELFuelCell initiated with a Buy at Dougherty
Target $2.45.
April 16, 2015
08:31 EDTTRGTTargacept says TC-6499 did not meet primary endpoint in Phase 1/2 study
Subscribe for More Information
April 15, 2015
07:36 EDTBLDPBallard Power receives fuel cell power module order for eight buses in China
Ballard Power has received an order from a Chinese customer to supply its FCvelocityTM-HD7 power modules for 8 buses to be deployed in a number of Chinese cities. Ballard expects to ship all of the modules in 2015.
April 13, 2015
11:28 EDTODPStarboard CEO says Staples, Office Depot merger 'likely to go through'
Says confident the potential merger will pass anti-trust scrutiny. Jeff Smith is speaking on CNBC.
April 9, 2015
09:18 EDTODP, PETMBofA/Merrill retail analysts hold an analyst/industry conference call
Subscribe for More Information
April 6, 2015
10:37 EDTTRGTTargacept says Pfizer terminates research & license agreement with Catalyst
In a regulatory filing from earlier, Targacept (TRGT) said: "As previously reported, on March 5, Targacept, Talos Merger Sub, a Delaware corporation and a wholly owned subsidiary of Targacept and Catalyst Biosciences, entered into an Agreement and Plan of Merger, pursuant to which, among other things, subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Merger Sub will merge with and into Catalyst, with Catalyst becoming a wholly owned subsidiary of Targacept and the surviving corporation of the merger. On April 1, Catalyst notified Targacept that Pfizer (PFE) would be exercising its right to terminate in its entirety the June 29, 2009, research and license agreement between Catalyst and Wyeth, which governs the development and commercialization of Catalystís leading human Factor VIIa product candidate for the treatment of hemophilia and surgical bleeding indications. On April 2, Pfizer provided Catalyst with its formal written notice of termination of the research and license agreement. Upon the June 1, effective date of the termination, the license and certain rights under the research and license agreement will terminate and revert to Catalyst. Catalyst has informed Targacept that Pfizer is committed to an orderly transfer of data, regulatory documentation and related technology under the agreement to Catalyst to enable Catalyst to continue the clinical development of this product candidate. Targacept is currently reviewing the implications of this event on the proposed Merger. In morning trading shares of Targacept are down almost 12% to $2.51.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use